论文部分内容阅读
目的:通过对比研究153Sm-EDTMP和唑来膦酸治疗前列腺癌骨转移,以了解153Sm-EDTMP治疗前列腺癌骨转移的疗效。方法:确诊前列腺癌骨转移患者55例,分两组,一组31例用153Sm-EDTMP按37.0 MBq/kg体重静脉注射治疗,一组24例用唑来膦酸4 mg加入0.9%氯化钠注射液100 ml中缓慢静滴。治疗前及治疗后1～2个月行99mTc-MDP骨扫描检查。结果:153Sm-EDTMP组疼痛缓解有效率为83.9%,骨代谢改变有效率为64.5%。唑来膦酸组疼痛缓解有效率为58.3%,骨代谢改变有效率为33.3%。经χ2检验,两组疼痛缓解有效率比较χ2=4.448,P=0.035,骨代谢改变有效率比较χ2=5.263,P=0.022,均有显著性差异。结论:153Sm-EDTMP是治疗前列腺癌骨转移较理想的药物。
OBJECTIVE: To compare 153Sm-EDTMP with zoledronic acid in the treatment of prostate cancer bone metastases to understand the clinical efficacy of 153Sm-EDTMP in treatment of bone metastases of prostate cancer. Methods: 55 patients with bone metastases from prostate cancer were divided into two groups. One group of 31 patients were treated with 153Sm-EDTMP intravenously at a dose of 37.0 MBq / kg body weight. A group of 24 patients were treated with 4 mg zoledronic acid plus 0.9% sodium chloride Inject 100 ml slow intravenous infusion. 99mTc-MDP bone scan was performed before treatment and 1 ~ 2 months after treatment. Results: 153Sm-EDTMP group had 83.9% effective rate of pain relief and 64.5% effective rate of bone metabolism. In the zoledronic acid group, the pain relief rate was 58.3% and the bone metabolic rate was 33.3%. The χ2 test showed that the effective rate of pain relief between the two groups was χ2 = 4.448, P = 0.035, and the effective rate of bone metabolism was χ2 = 5.263, P = 0.022, all of which were significantly different. Conclusion: 153Sm-EDTMP is an ideal drug for the treatment of bone metastasis of prostate cancer.